Results 171 to 180 of about 11,256 (207)
Some of the next articles are maybe not open access.
Clinical Cancer Research, 2019
Abstract Ovarian cancer (OC) is one of the most lethal female malignancy which accounts for just 2.5% of female cancer cases but 5% of deaths because of low survival. 90% of OC are epithelial ovarian cancer (EOC), with an overall 5-year relative survival rate of 47% and only 29% for patients diagnosed with distant-stage.
Lu Liu +8 more
openaire +1 more source
Abstract Ovarian cancer (OC) is one of the most lethal female malignancy which accounts for just 2.5% of female cancer cases but 5% of deaths because of low survival. 90% of OC are epithelial ovarian cancer (EOC), with an overall 5-year relative survival rate of 47% and only 29% for patients diagnosed with distant-stage.
Lu Liu +8 more
openaire +1 more source
PARPi: Efficacy in Hereditary Breast Cancer
2021Breast cancer (BC) with germline pathogenic variants of BRCA1 or BRCA2 is found in approximately 5% of Japanese BC patients. BRCA1/2-associated BC with homologous recombination (HR) deficiency is potentially sensitive to DNA damage agents, including platinum agents and PARP (poly(ADP-ribose) polymerase) inhibitors.
openaire +1 more source
Iron: The Secret Ingredient Breaking PARPi Resistance
Cancer DiscoverySummary: PARP inhibitors (PARPi) are used as a first-line treatment option for cancers with BRCA1/2 mutations, yet a significant number of patients show a limited response to these agents. In the present study, Lei and colleagues demonstrate that PARPi promote increased ferroptosis sensitivity and this can be ...
Hamed Alborzinia +1 more
openaire +2 more sources
[18F]PARPi-PET in locally advanced oral cavity carcinoma
Oral Oncology, 2019Treatment of locally advanced oral cavity carcinoma (OCC) generally includes surgical resection followed by adjuvant radiotherapy (RT) [1]. Adjuvant concurrent chemoradiotherapy (CRT) is usually required in case of extranodal extension and/or positive surgical margins [1].
De Felice F., Tombolini V.
openaire +3 more sources
PARPi post PARPi: Clarity from the Clearity real world experience (164)
Gynecologic Oncology, 2022Jessica Jou +3 more
openaire +1 more source
PARPi focus the spotlight on replication fork protection in cancer
Nature Cell Biology, 2017PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients.
openaire +2 more sources
Introduction to PARPi Clinical Trials and Future Directions
2015This chapter gives a brief overview of the entry of PARP inhibitors (PARPi) into the clinic, and the progress made in the last decade. These agents started clinical development in combination with DNA damaging chemotherapy, however, the emergence of the preclinical evidence supporting use as single agents in defined patient populations has led to a ...
Ruth Plummer, Yvette Drew
openaire +1 more source
Neoadjuvant PARPi for Urothelial Carcinoma: Between Lifeline and Desperation
Future Oncology, 2021Georges Abi Tayeh +5 more
openaire +2 more sources